Robert Gottlieb - Researcher Profile

Publications

3 shown

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen , Ajay Nirula , Barry N. Heller +19 more

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas th...

2020 New England Journal of Medicine 1412 citations

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Christoph D. Spinner , Robert Gottlieb , Gerard J. Criner +27 more

ClinicalTrials.gov Identifier: NCT04292730.

2020 JAMA 1250 citations

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Robert Gottlieb , Carlos Vaca , Roger Paredes +27 more

Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of...

2021 New England Journal of Medicine 1224 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 3,886
Institution: Baylor University Medical Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-8376-8709

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.